↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
TriSalus Life Sciences$TLSI · filed: grew revenue 53.4% in FY2025 to $45MRotting at the dockTrillion Score 574Fall Risk HighNext year $43.1M–$107M sealedCheck ▾Close ▴
What TriSalus Life Sciences filed
Grew revenue 53.4% in FY2025 to $45 million, operating margin -59.7% against a 1.2% median for surgical & medical instruments & apparatus, equity -95.8% of assets. Every figure links to the filing it came from on TriSalus Life Sciences’s card. Rotting at the dock: four or more warning signs. Trillion Score 574, #22 of 116 in its field; Fall Risk High (how it is measured).
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $43.1M and $107M, an 80% range sealed on 27 Sept 2026 · receipt #ef8b06 · graded in public by the revenue in TriSalus Life Sciences’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
TriSalus exits via SPAC with **$131M** pro forma cash, **18-month** runway, and Q4 2025 survival data catalyst in liver cancer pivotal trial.
$315 million
pro forma enterprise value
$69 million
in trust as of December 2024
$40 million
PIPE led by existing TriSalus shareholders including Longitude Capital…
$22 million
in current cash
TriSalus Life Sciences announced a definitive merger agreement with Westminster Health Acquisition Corporation that will take the oncology-focused medical device company public and fund Phase III trials for its pressure-enabled drug delivery platform. The transaction values TriSalus at approximately $315 million pro forma enterprise value, with the combined entity expected to trade on Nasdaq under ticker TLSI by Q3 2025.
The Westminster SPAC held $69 million in trust as of December 2024, supplemented by a $40 million PIPE led by existing TriSalus shareholders including Longitude Capital and Santen Pharmaceutical. TriSalus disclosed $22 million in current cash, putting total pro forma liquidity near $131 million before transaction expenses. The company burned approximately $35 million in 2024 across three ongoing clinical programs, suggesting an 18-month runway at current spend before needing additional capital. Westminster's sponsor, led by former Cigna executive David Cordani, waived earnout provisions and accepted a reduced promote structure that releases shares only above $12.50 post-merger price thresholds.
TriSalus manufactures the Pressure-Enabled Drug Delivery system, a catheter-based platform that creates transient increases in intratumoral pressure to enhance chemotherapy penetration in solid tumors. The technology bypasses systemic toxicity by delivering existing oncology drugs directly into the tumor vasculature under controlled pressure gradients. The company holds 37 issued patents covering pressure modulation mechanics and has 510(k) clearance for the delivery catheter as a vascular access device. Current trials focus on hepatocellular carcinoma and pancreatic cancer, where the platform combines with standard-of-care agents like gemcitabine and cisplatin. Enrollment in the PERIO-03 liver cancer study reached 187 patients across 22 sites as of January 2025, with interim survival data expected in Q4 2025.
The SPAC route returns after biotech de-SPAC transactions dropped 91% between 2021 and 2023, with only four healthcare SPAC mergers closing in 2024 compared to 63 in 2021. TriSalus represents a shift toward later-stage assets with visible catalysts rather than pre-revenue platform plays. The company reported $2.1 million in 2024 revenue from international device sales and physician training fees, a modest but real commercial footprint. Management disclosed $180 million in cumulative equity raised since the 2019 spinout from AngioDynamics, which retained a 12% stake now worth approximately $38 million at merger valuation. The filing shows TriSalus paying AngioDynamics a 3.5% royalty on future product sales, capped at $25 million lifetime.
Allocators should track three sequences. The Westminster shareholder vote occurs approximately 45 days post-S-4 effectiveness, likely mid-May 2025, with redemption rates determining final cash to balance sheet. PERIO-03 interim analysis reads out in Q4 2025 and will either validate the pressure-modulation thesis with survival data or send the stock below cash value if endpoints miss. The company must initiate its pancreatic cancer pivotal trial by Q1 2026 to maintain Longitude Capital's $15 million milestone tranche, creating a forced capital deployment clock. Separate from the merger, TriSalus maintains an exclusive distribution agreement with Guerbet SA covering 14 European markets, generating mid-single-digit percentage royalties that hit TriSalus books with a one-quarter lag.
AngioDynamics announced in its January 2025 earnings call that it would monetize the retained TriSalus position within six months post-merger, adding 7 million shares of potential selling pressure to a float that will total approximately 38 million shares at close. The lockup agreement permits AngioDynamics to sell 25% of its stake every 90 days starting 180 days post-close, meaning 1.75 million shares become available in Q1 2026 regardless of stock performance.
Branded by POPS4 · proof in 60 seconds
For the principal
AngioDynamics dumps 7M shares post-lockup starting Q1 2026; track redemption rate at shareholder vote for actual cash to balance sheet.
For the operator
PERIO-03 interim data in Q4 2025 is the real merger thesis; $131M cash covers 18 months at $35M annual burn before dilution event.
For the house
Short setup if Westminster redemptions exceed 65% or PERIO-03 misses; otherwise hold cash-adjusted floor with $38M international revenue optionality through Guerbet.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
